With new developments in Dry AMD and Geographic Atrophy (GA) care, are you equipped with the best tools and techniques to diagnose and manage these challenging conditions? This essential read dives into today’s most effective clinical strategies, providing you with the knowledge you need to optimize patient outcomes.

Explore expert insights into the diagnosis and management of Dry AMD and Geographic Atrophy—from early detection to complement inhibition therapies and real-world clinical applications. The supplement also highlights risk assessment approaches for identifying fast progressors and offers practical ways to enhance patient education and adherence to long-term injection therapies.

What’s Inside the Supplement:

Highlights from the 2023 EURETINA Clinical Survey Data on Dry AMD and GA
By Anat Loewenstein, MD, MHA

“The majority of respondents favor OCT as
their preferred diagnostic method.” – Anat Loewenstein

Diagnostic Strategies for Early Diagnosis and Monitoring
By Stela Vujosevic, MD, PhD, FEBO, FARVO

“While best corrected visual acuity is
commonly used for functional assessment,
it is not the most effective method for
evaluating GA progression.” – Stela Vujosevic

Identifying Patients at Risk for Fast Progression
By Adnan Tufail, MBBS, MD, FRCOphth

“Multimodality is very useful initially, but
for follow-up, automated OCT metrics
could greatly enhance patient
management.” – Adnan Tufail

C5 Complement Inhibition Treatment in Practice
By Arshad M. Khanani, MD, MA, FASRS

“Safety is paramount, especially when it
comes to new drugs.” – Arshad M. Khanani

Real World Experiences With C3 Complement Inhibition Treatment for GA
By Jeff Heier, MD

“The key for GA patients is having a
thorough discussion of the benefits and
risks.” – Jeff Heier

Optimizing Patient Education and Adherence With Injection Therapies
By Nicole Eter, MD

“Clearly communicate that this is a long-
term treatment for a chronic disease.” – Nicole Eter

Access the Full Supplement on EURETINA’s Education Platform

Independent Medical Education supported by Astellas Pharma and Apellis.